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Abstract 
 
Objective To determine facility-level and service-related factors affecting the prescription of 
sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment for malaria during 
antenatal clinic visits in Kenya. 
 
Methods Using data from the 2010 Kenya Service Provision Assessment, data analysis was 
performed on 1,183 client antenatal visits. Logistic regression was used to analyze the effects of 
facility and service-related factors on sulfadoxine-pyrimethamine prescription.  
 
Results Facility managing authority, drug availability, and number of previous SP doses were 
significantly associated with prescription. No statistically significant relationships were found 
between IPTp guideline availability, supervision, quality assurance, or water and SP prescription.  
 
Conclusion Among health facilities in Kenya, facility and service-delivery factors impact 
effectiveness of national malaria policy. This study identifies opportunities to improve SP/IPTp 
coverage by focusing on supply-side mechanisms.    
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Introduction  
Despite great progress in prevention and treatment, malaria caused nearly 700,000 deaths and an 
estimated 207 million infections in 2012.
1
 Pregnant women and children are at particularly high 
risk for malaria transmission and adverse outcomes.
1
 Malaria in pregnancy (MIP) poses great risk 
to not only the woman, but also to the fetus and the newborn child through increased risk of 
maternal and infant anemia, low birth weight, spontaneous abortion, and premature birth.
1
 In 
2007, approximately 32 million women in Africa became pregnant in malaria endemic areas, 
making the prevention of malaria in pregnancy a high priority for governments and 
policymakers.
2
  
The World Health Organization (WHO) recommends a package of highly effective interventions 
to prevent and treat malaria in pregnancy: provision of insecticide-treated bed nets and 
intermittent preventive treatment (IPTp) for prevention and proper clinical management for 
treatment.
1
 IPTp using sulfadoxine-pyrimethamine (SP) has been shown to prevent adverse 
consequences of malaria on both maternal and fetal outcomes and is extremely cost-effective.
3
 
Many Sub-Saharan African countries integrate these interventions into routine antenatal clinic 
(ANC) visits in regions with stable malaria transmission.
4
 Current IPTp guidelines recommend 
prescribing SP at every ANC visit beginning in the second trimester, with at least one month 
between doses.
4
 The WHO recommends a minimum of 4 ANC visits, with the initial visit 
occurring in the first trimester.
4
 SP/IPTp should not be administered to HIV+ women who are 
receiving co-trimoxazole prophylaxis due to contraindication.
4
 IPTp guidelines have evolved 
through multiple iterations, with the most recently released guidelines in 2012 simplified to 
increase provider comprehension and uptake.  
In Kenya, nearly 70% of the population is at risk of malaria.
5
 According to the Demographic and 
Health Survey conducted in 2008 – 2009, 92% of women attended at least one ANC visit, 39% 
attended two to three times, and 47% attended four or more visits.
6
 Furthermore, only 15% of 
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women obtained ANC care in their first trimester and only 52% before the sixth month of 
pregnancy.
6
 Kenya’s current malaria control strategy recommends that all pregnant women living 
in moderate to high malaria transmission areas should receive at least two free SP/IPTp doses, 
and strives to achieve 80% coverage.
7,8
 This strategy was in place in 2010 when the survey was 
conducted. In 2010, despite high ANC attendance, only 46% of women received at least one 
dose, and 25% received >2 doses of SP during their pregnancy in the previous two years.
9
 
However, this is still an increase from 4% receiving >2 doses in 2003.
6
 High ANC attendance rate 
coupled with low SP/IPTp uptake highlights a large number of missed opportunities for malaria 
prevention amongst this high-risk group.  
The majority of studies on SP/IPTp delivery have focused on individual characteristics of women 
and their households to identify factors related to SP/IPTp uptake, such as education, income, 
maternal age, and parity.
10,11
 Service-delivery barriers to SP/IPTp delivery have been previously 
identified as well, such as: unclear guidelines and policies, medicine stock outs, lack of water and 
cups, and lack of supervision, training, and quality assurance.
10,11,12,13
  In 2013, a systematic 
review and meta-analysis on MIP literature was conducted to identify the determinants of 
SP/IPTp uptake.
14
 The review highlighted a deficiency of literature on the service-delivery factors 
that result in a bottleneck experienced at the service level.
14
 This paper seeks to identify key 
factors contributing to this bottleneck, which will allow programs and policies to more effectively 
improve SP/IPTp coverage during routine ANC visits. This study reviewed data from 1,183 ANC 
visits across Kenya and used regression models to assess predictors of SP/IPTp prescription. We 
are interested in facility-level factors, service-related factors and client characteristics that may 
influence prescription administration. Facility-level factors include facility managing authority 
and facility infrastructure (water access and drug availability); service-related factors include 
education (guideline availability and training) and management (supervision of service providers 
and quality assurance); and client-level factors include gestational age, gravidity, and previous 
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number of SP/IPTp doses. In particular, we predict a positive association between training, IPTp 
guideline availability and supervision variables and SP/IPTp prescription. These variables were 
selected based on previous studies or because of an anticipated potential association.  
Conceptual Model  
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Methods 
 
Data  
 
The 2010 Kenya Service Provision Assessment (KSPA) is a nationally representative survey of 
703 health facilities and is designed to provide information on the availability and quality of 
health services. Data was collected from January 21, 2010 – May 18, 2010 by the Kenya National 
Coordinating Agency for Population and Development along with the Ministry of Public Health 
and Sanitation (MOPHS), Ministry of Medical Services, and Kenya National Bureau of Statistics. 
Data collection tools – facility audit, exit interview, observation protocol, and provider 
questionnaire – were adapted from MEASURE Demographic and Health Surveys (DHS) for 
Kenya and administered in all provinces in hospitals, health centers, clinics, maternities, 
dispensaries, and stand-alone voluntary counseling and testing facilities. Facilities were randomly 
selected from a Kenya Master Facility List, but hospitals, maternity facilities and stand-alone 
VCTs were oversampled. Health providers were selected based on presence in the facility on the 
day of the survey. The observations are associated with 389 health facilities and 455 health 
workers.  
 
Clients were selected based on the number of expected clients divided by five to determine the 
nth interval for selecting the next observed client. Client and provider response rates were not 
available. Data for both health providers and clients were weighted to account for over or under 
sampling. Health providers and clients were not compensated for their participation in the survey.  
In this study, ANC visits during the second and third trimester were analyzed to assess the factors 
that influence the prescription of SP/IPTp. Pregnancies in their 15th or fewer weeks were 
excluded from this analysis as SP/IPTp should not be administered during the first trimester.
15
 
Analysis excluded observations from Nairobi (n=119) because it is a malaria-free zone and has 
the lowest proportion of women receiving SP/IPTp from an ANC visit (19%).
6
 Additionally, 
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region was excluded from the analysis because although malaria transmission zones vary 
dramatically between them, the proportion of SP/IPTp prescription did not.  
Each observation in the sample (n=1,183) utilizes data from all four of the collection tools 
previously mentioned and each client is considered an observation and is measured only once. 
IRB approval was requested and, due to the nature of the data, we were granted an exemption.  
Measures  
SP/ITPp Prescription. The dependent variable, and our outcome of interest, is the prescription or 
administration of SP/IPTp during an ANC visit. Prescription and administration are combined in 
the observation questionnaire. The data were collected during the provider-client observation by 
the observer and have a binary outcome of “prescribed” or “not prescribed”. Observations with an 
“unknown” outcome were dropped (n=9).  
Managing Authority. Facilities may be classified based on ownership into 1 of 4 categories: 
government/local municipality, non-governmental organization (NGO), private (for-profit), or 
faith-based.  
Water Availability. The facility audit questionnaire assessed facilities’ most common water 
source. Due to over 14 potential water source options, our definition of water availability 
collapsed water source into four categories: “non-piped offsite”, “non-piped onsite”, “piped onto 
grounds”, and “piped into facility”.  Less than 500 meters from the facility is considered “on-
site”, while >500 meters is “off-site”. Water availability is included in the analysis because 
SP/IPTp should be administered through directly observed treatment (DOT); therefore, water 
inaccessibility may inhibit a provider from prescribing the treatment. 
SP Availability. The facility audit measured the availability of sulfadoxine-pyrimethamine (SP) 
antimalarial drug in the ANC consultation room. SP was found to be: 1, available and observed; 
2, reported available but unobserved; or 3, unavailable. In accordance with KSPA convention, 
items reported available but unobserved by the interviewers were also considered unavailable; 
therefore, we combined the unobserved and unavailable categories.
16
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IPTp Guideline Availability. The facility audit captured the availability of IPTp protocol 
guidelines in the ANC consultation room. Guidelines were determined to be: 1, available and 
observed; 2, reported available but unobserved; or 3, unavailable. Following KSPA convention, 
items reported available but unobserved by the interviewers were also considered unavailable; 
therefore, we combined 2 and 3.
16
   
IPTp Training. Providers reported to have received IPTp-specific training (pre-service or in-
service) within the previous year, within the previous 2-3 years, or never.   
Quality Assurance. Quality assurance means that the facility has a formal review system or 
comparison of work to a standard, which is measured through the facility audit. The following 
question was used to collect this information: “Does this facility routinely carry out quality 
assurance activities? By this I mean some formal review system or comparison of work or system 
to a standard?” Responses were recorded as either “Yes”, “No” or “I don’t know”. An “I don’t 
know” response was considered “No” in this analysis.  
Provider Supervision. This variable measures the last time a provider received supervision, as 
reported by the provider. In this analysis, outcomes were grouped into three categories: receiving 
supervision in the past year, receiving supervision over a year ago, and never receiving 
supervision. We collapsed providers receiving supervision in the past 3 months, 6 months, and 7-
12 months into one category due to the similarities between these three groups and to reduce 
number of variables in the model.  
Client characteristics. Client characteristics included gestational age, gravidity, and previous SP 
doses. Gestational age ranges from 16-40 weeks. Gravidity is binary and based on a provider’s 
yes/no response to the question: “Is this the client’s first pregnancy?” Previous SP dose is a 
constructed variable based on the assumption that a provider would note giving SP on the client’s 
health card. This assumption is supported by over 99% of observed providers writing on the 
client’s health card in this survey. Information on number of SP doses was obtained from the 
ANC card during a client exit interview. If the provider prescribed SP during the visit, we 
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subtracted one SP dose to determine doses prior to the ANC visit. Those with 3 or more doses 
were grouped together because there were only a few observations with 4 doses, there was not a 
difference in prescription between them and those with 3, and the current literature only provides 
a distinction between 1, 2, and >3 doses of SP/IPTp.  
Analytic techniques  
Observations studied in this analysis are based on individual client ANC visits (n=1,183). Cross 
tabulation and descriptive analyses were used to describe general characteristics of the study 
population and sample facilities.  
 
Binomial logistic regression was used to examine the relationship between service-delivery 
factors and prescription of SP/IPTp, controlling for a variety of client characteristics. The first 
model tests the multivariate effects of facility-level factors on the likelihood of SP/IPTp 
prescription. The second model tests these relationships again but adds service-related variables. 
The third model controls for client characteristics. Data were weighted during analysis to account 
for differentials caused by oversampling and under sampling and thus to represent the actual 
distribution of facilities in the country.  
 
Margin estimates (predictive margins) were produced based on the fitted final logistic regression 
model. These estimates illustrate the predicted prescription of SP/IPTp given that other variables 
have been controlled for under the model. All data analyses were completed with STATA 13 
software. 
Results 
The descriptive analysis revealed that of the 1,183 ANC clients observed, 73% (n=872) were 
prescribed SP/IPTp by their health service provider. The mean client age was 25, and the mean 
gestational age was 30 weeks. 91% of these ANC visits were to facilities with SP/IPTp available, 
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and 46% of providers interviewed had received training on IPTp. Table 1 summarizes some of 
these key, general findings and provides an overview of the study population and some of the 
variables.  
Table 1. General Characteristics of ANC Clients & Facilities 
Total Clients 1,183 
Age Range of Clients 14-53 
Mean Age of Client (SD) 25 (5.5) 
Gestational Age in Weeks (SD) 30 (5.7) 
Client’s 1st Pregnancy (%) 414 (31) 
ANC Visits with SP Prescribed (%) 872 (73) 
ANC Visits with SP Available (%)  1,210 (91) 
ANC Visits with IPTp Guidelines Available (%) 580 (48) 
ANC Visits with H2O Available Onsite (%)  1,240 (94) 
ANC Providers Received IPTp Training (%) 594 (46) 
 
Cross tabulations were utilized to compare the various study variables to our outcome of interest: 
SP/IPTp prescription. The analysis showed that over 70% of clients attending ANC at either a 
government or NGO facility received SP/IPTp, while less than 50% received the anti-malarial at a 
private or faith-based facility. 72% of clients to facilities with SP available in the consultation room 
were prescribed SP/IPTp, but only 31% were prescribed the drug if it was unavailable. SP/IPTp 
prescription was only slightly different (3%) between facilities with IPTp guidelines and those 
without, 75% and 72%, respectively. Similarly, training did not appear to have a strong influence 
on prescription with 73% of providers without training, 64% with training 2-3 years ago, and 75% 
with training in the past year prescribing the drug. There is a dramatic difference between women 
who had received 1 or no doses prior to the visit (79% and 86%, respectively) and women who had 
previously received 2 or 3 or more (31% and 34%, respectively). Table 2 summarizes the difference 
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in SP/IPTp prescription by all facility-level, service-related, and client characteristics in the 
conceptual model.  
Table 2.  % of Clients Prescribed SP/IPTp by Facility-Level Variables,  
Service-Related Factors, and Client Characteristics 
 
Characteristic  
Clients Prescribed SP/IPTp 
Percent* Number 
All ANC Clients (2
nd
 or 3
rd
 trimester) 73 872 
Facility-Level Factors 
Managing Authority 
Government/Local Municipality 79 732 
NGO/Not-for-Profit 71 11 
Private/For-Profit 38 32 
Faith-based/Mission 47 97 
H2O Access 
Piped Facility 72 465 
Piped Grounds  70 30 
Non-piped Onsite 70 315 
Non-piped Offsite 89 62 
SP Availability  
Available in ANC Room 75 850 
Unavailable in ANC Room 31 22 
Service-Related Factors 
IPTp guidelines available at clinic 
Available 75 404 
Unavailable 72 413 
IPTp Training 
None 73 451 
w/in 2-3 years 64 110 
w/in past year 75 301 
Quality Assurance  
Available 72 505 
Unavailable 73 367 
Provider Supervision 
w/in past year 75 766 
Over a year ago 76 42 
Never 47 64 
Client Characteristics 
Gravidity  
1
st
 pregnancy 74 281 
2nd or greater pregnancy 72 591 
# of Previous SP Doses 
0 86 472 
1 79 301 
2 31 56 
                  > 3 34 8 
        *Calculated from weighted population totals and exclusion of Nairobi 
subpopulation. May not exactly match corresponding sample based 
numbers.  
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Logistic regression revealed significant associations in all three of our models. In our first model, 
which included facility-level factors only, managing authority, water access, and SP availability 
were all found to significantly affect the prescription of SP/IPTp. Table 3 summarizes these 
results. Attending ANC at a private facility versus a government facility resulted in reduced odds 
of prescription, with the odds of prescription at a private facility 0.20 (95% CI: 0.10-0.41) times 
the odds of prescription at a government facility. A similar negative association was found with 
faith-based facilities: the odds of prescription at a private facility were 0.30 (95% CI: 0.17-0.52) 
times the odds of prescription at a government facility. If SP is available in the ANC consultation 
room, the provider was 5.9 (95% CI: 2.42-11.10) times more likely to prescribe SP/IPTp than if 
SP was unavailable. Out of the four categories of water sources, the only one found to 
significantly affect prescription (as compared to our referent group: piped water into the facility) 
was a non-piped offsite water source, which was associated with 2.45 (95% CI: 1.07-5.61) times 
greater odds of prescription. The addition of service-related factors in Model 2 removed water 
access as a significant predictor and altered the point estimates of the effects of SP availability 
and managing authority. In this model, prescription of SP/IPTp at private facilities and at faith-
based facilities were 0.16 (95% CI: 0.08-0.34) and 0.35 (95% CI: 0.21-0.58), respectively, times 
the odds of prescription at a government facility. The odds of prescription, given that SP is 
available in the consultation room, were now 4.34 (95% CI: 1.91-9.87) times the odds of 
prescription if SP is unavailable. No service-related variables were significantly associated with 
the outcome in this model. The third model controlled for client characteristics (gestational age, 
gravidity, and previous SP doses), which strengthened the associations between managing 
authority, SP availability, and training variables and the outcome. Private facilities are now only 
0.12 (95% CI: 0.04-0.32) times as likely as government facilities to prescribe SP/IPTp, while 
faith-based are 0.24 (95% CI: 0.13-0.45) times the odds of government facilities. The point 
estimate for the effect of SP availability on prescription jumped from an OR of 4.34 in Model 2 to 
9.21 in Model 3. If SP was available in the consultation room, a provider was 9.2 (95% CI: 3.91-
14 
 
21.64) times more likely to prescribe SP than if SP was unavailable. Surprisingly, in this third 
model, IPTp training within the previous 2-3 years was found to be negatively associated with 
SP/IPTp prescription (OR: 0.45 95% CI: 0.24-0.85) compared to no reported IPTp training. The 
only client characteristic found to be significantly associated with the outcome was the number of 
previous doses of SP. If the client had 2 previous doses or >3 then the provider was significantly 
less likely to prescribe SP/IPTp. The odds of prescription if the client had 2 or >3 previous doses 
was 0.06 (95% CI: 0.03-0.14; 95% CI: 0.02-0.17, respectively) times the odds of prescription if 
the client had no previous doses. IPTp guideline availability, gestational age, gravidity, provider 
supervision, water access, and quality assurance did not have a significant impact on the odds of 
SP/IPTp prescription.  
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Table 3.  ORs for Client Receipt of SP/IPTp Prescription, Kenya Service Provision Assessment, 2010 
 SP Prescription 
Characteristic 
Model 1: 
Adjusted OR 
Facility Level 
Characteristics 
(95% CI) 
Model 2: 
Adjusted OR
 
Model 1 + Service-
Related 
Characteristics 
(95% CI)
 
Model 3: 
Adjusted OR
 
Model 2 + Client 
Characteristics (95% CI) 
Facility-Level Factors    
Managing Authority 
Government 
NGO/Not-For-Profit 
Private/For-Profit                               
Faith-Based  
 
1.00 [Referent] 
0.81 (0.28-2.34) 
0.20 (0.10-0.41)*** 
0.30 (0.17-0.52)*** 
 
1.00 [Referent] 
1.22 (0.36-4.09) 
0.16 (0.08-0.34)*** 
0.35 (0.21-0.58)*** 
 
1.00 [Referent] 
1.18 (0.16-8.74) 
0.12 (0.04-0.32)*** 
0.24 (0.13-0.45)*** 
H2O Access 
    Piped Facility 
    Non-piped Offsite 
    Non-piped Onsite 
    Piped Grounds 
 
1.00 [Referent] 
2.45 (1.07-5.61)* 
0.84 (0.53-1.31) 
0.10 (0.34-2.91) 
 
1.00 [Referent] 
2.01 (0.83-4.88) 
0.87 (0.54-1.40) 
0.42 (0.19-1.22) 
 
1.00[Referent] 
1.58 (0.63-3.94) 
0.94 (0.53-1.66) 
0.75 (0.28-2.05) 
    
SP Availability  
     Available 
 
5.9 (2.42-11.10)*** 
 
 
4.34 (1.91-9.87)*** 
 
 
9.21 (3.91-21.64)*** 
 
Service-Related Factors    
Guideline Availability 
Available  
 
 
 
1.13 (0.71-1.80) 
 
1.38 (0.80-2.38) 
IPTp Training 
None  
w/in 2-3 years 
w/in past year 
 
 
 
1.00 [Referent] 
0.59 (0.33-1.04) 
0.71 (0.42-1.21) 
 
1.00 [Referent] 
0.45 (0.24-0.85)* 
0.61  (0.32-1.16) 
Quality Assurance    
   Available   1.08 (0.68-1.73) 1.01 (0.56-1.83) 
Provider Supervision    
   w/in past year 
   over a year ago 
   never  
 1.00 [Referent] 
1.50 (0.66-3.41) 
0.54 (0.27-1.10) 
1.00 [Referent] 
1.56 (0.62-3.98) 
0.60 (0.24-1.92) 
Client Characteristics    
Gestational Age
2 
  0.96 (0.91-1.01) 
Gravidity 
   First Pregnancy 
  
 
 
1.17 (0.71-1.92) 
# of Previous SP Doses
3 
0 
1 
2 
>3  
  
 
 
1.00 [Referent] 
0.58 (0.33-1.03) 
0.06 (0.03-0.14)*** 
0.06 (0.02-0.17)*** 
  *p value < 0.05 ** p value < 0.01 *** p value < 0.001  
   2. Continuous variable ranging 16-40 weeks pregnant  
   3. Refers to the number of SP/IPTp doses the client had received prior to that visit  
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After completing the third logistic regression model, a post estimation of the marginal 
probabilities of each of the variables was conducted. Table 4 shows the marginal probabilities for 
each of the study variables. Holding everything else in the model constant, if a woman were to 
visit a government facility there is a 76% chance she will be prescribed SP/IPTp, 79% at an NGO 
facility, 40% at a private facility, and 54% at a faith-based facility. There is a 75% chance of 
prescription if SP is available in the room, but only a 38% chance if it is unavailable. A woman 
who has no previous doses of SP has an 83% chance of receiving  prescription, while a woman 
with 1 previous dose has a 77% chance, a woman with 2 previous doses or >3 doses a 35% 
chance.  
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Table 4.  Marginal Probabilities* for Client Receipt of SP/IPTp 
 Prescription, Kenya Service Provision Assessment, 2010 
Characteristic  
Clients 
Prescribed 
SP/IPTp 
Percent* 
Facility-Level Factors  
Managing Authority  
Government/Local Municipality 76 (0.73-0.80) 
NGO/Not-for-Profit 79 (0.54-1.03) 
Private/For-Profit 40 (0.23-0.58) 
Faith-based/Mission 54 (0.42-0.64) 
H2O Access  
Piped Facility 72 (0.67-0.77) 
Piped Grounds  68 (0.55-0.81) 
Non-piped Onsite 71(0.65-0.77) 
Non-piped Offsite 77 (0.68-0.87) 
SP Availability   
Available in ANC Room 75 (0.72-0.79) 
Unavailable in ANC Room 38 (0.23-0.52) 
Service-Related Factors  
IPTp guidelines available at clinic  
Available 74 (0.69-0.78) 
Unavailable 70 (0.64-0.75) 
IPTp Training  
None 76 (0.71-0.80) 
w/in 2-3 years 65 (0.58-0.72) 
w/in past year 69 (0.63-0.76) 
Quality Assurance   
Available  72 (0.66-0.77) 
Unavailable 72 (0.69-0.77) 
Provider Supervision  
w/in past year 72 (0.68-0.76) 
Over a year ago 78 (0.68-0.88) 
Never 65 (0.52-0.78) 
Client Characteristics  
Gravidity   
1
st
 pregnancy 73 (0.68-0.78) 
2nd or greater pregnancy 71 (0.67-0.76) 
# of Previous SP Doses  
0 83 (0.79-0.87) 
1 77 (0.71-0.83) 
2 35 (0.22-0.47) 
>3  35 (0.18-0.52) 
*Probability that a woman would be prescribed SP/IPTp 
controlling for all other variables in the model.  
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Discussion  
The analysis found two facility-level characteristics (managing authority and SP availability), one 
service-related factors (IPTp training), and one client characteristic (number of previous SP/IPTp 
doses) significantly affecting the odds of SP/IPTp prescription. Water source, guideline 
availability, quality assurance, provider supervision, gestational age, and gravidity were not 
associated with SP/IPTp prescription.  
The association between facility managing authority and SP/IPTp prescription is one of the most 
significant results of this study: women who attend faith-based or for-profit facilities are 
significantly less likely to receive a prescription than women who attend government or not-for-
profit facilities. This presents an opportunity for the government and its partners to ensure that 
outreach, education, and supervision is occurring at private and faith-based facilities. These 
facilities and their significantly reduced odds of prescription cannot be overlooked as 11% of 
pregnant women in our data set attended faith-based facilities and 5% attended for-profit.  
 
Although a facility’s main water source did not significantly impact drug prescription in the final 
model, the results show an overall protective effect of non-piped, offsite water. The lack of 
significance and slight protective effect of non-piped, offsite water was unexpected; water is 
needed to implement DOT and several previous studies have shown that water access affects 
IPTp uptake.
14,17
 The effect of water should be further explored both in this dataset and 
elsewhere. Alternatively, water source was found to indeed affect the administration of directly 
observed treatment (DOT). Nearly 36% of those prescribed SP/IPTp had the pills in their 
possession after the appointment despite DOT policy: clients should swallow pills in the presence 
of the provider.
18
 The greatest proportion of women with the pills still in their possession after the 
visit were at facilities with “non-piped offsite” water. The greatest number of DOT-adherers were 
at facilities with piped water in the facility. This finding makes intuitive sense but is important for 
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policymakers and health programs because although water source may not affect prescription, it 
may affect correct administration and eventual coverage of SP/IPTp.  Fortunately, 96% of clients 
with the pills in their possession after their appointment claim they were told how to take it.  
 
The relationship of SP availability to IPTp prescription intuitively makes sense: If a medication is 
not available a provider is less likely to prescribe or provide it.
14,17
 Out of the 333 clients not 
prescribed SP, 15% of them were at a facility with no SP that day. It was encouraging to see that 
94% of facilities had SP available at the time of the survey and only 8% reported having a stock 
out within the previous 6 months. According to the FY2014 Kenya Malaria Operational Plan, no 
facilities have experienced stock outs in the previous three years.
5
 If this is true, this is a 
significant accomplishment and every effort should be made to ensure the continued strength of 
their supply chain and commodity management system.  
 
Surprisingly, the third model in our analysis showed that provider training on IPTp guidelines in 
the previous 2-3 years was significantly negatively associated with IPTp prescription when 
compared with providers who had no training. Providers who received training in the previous 
year were expected to have a higher likelihood of SP/IPTp prescription, but they were found in 
this study to be slightly less likely than those without training to prescribe (69% and 76%, 
respectively).
11,14,17,19,20 
Training quality may be an important factor in this variable, but we are 
unable to take this into account. Similar to the effects of water source, the effect of IPTp-specific 
training on SP/IPTp prescription should be further examined.  
 
 Guideline availability did not have a significant impact on SP/IPTp prescription in our analysis, 
but was found to be a significant predictor in previous studies.
20,21
 Our finding could be a result of 
the available guidelines being unclear, which has been previously documented in several 
studies.
11,14,17,19,20
 If guidelines are unclear, then their presence may not significantly impact 
20 
 
provider’s behavior. Without having information on provider’s perceptions of the guidelines it is 
hard to determine their clarity, although the release of a new WHO IPTp policy in 2012, and an 
initiative by the U.S. President’s Malaria Initiative in Kenya to simplify the guidelines, will 
hopefully improve guidelines to ensure that they are a supportive tool for providers.
4,5
  
 
Previous SP/IPTp doses significantly impacted prescription in this study: women who had 
previously received 2 or more doses were much less likely to receive a prescription than those 
who had previously received only 1 or 0 doses. This finding may highlight the potential impact of 
policy wording on coverage. The national policy in 2010, when this survey was administered, 
stated that women should receive “at least 2 doses.” Service providers appear to have focused on 
the attainment of at least two doses rather than the continued protection afforded by additional 
doses. A recent meta-analysis and systematic review found that 3 or more doses of SP were 
associated with fewer low birth weight infants, higher birth weight, and less placental malaria 
than those women who received 2 or fewer doses.
22
 The findings from this meta-analysis and 
systematic review support the WHO’s recent recommendation that women should receive at least 
3 doses; but, it is important for policymakers and programmers to recognize that service providers 
might now focus on achieving 3 doses, rather than striving to attain additional doses, even if the 
timing is appropriate and a positive dose-dependent association exists.
3,23
  
 
This study had several limitations. The dataset did not allow for identification of HIV+ women on 
daily cotrimoxazole chemoprophylaxis, which is contraindicated with SP/IPTp, and therefore 
should not be taken with SP/IPTp.
15
 Consequently, we are unable to determine if the failure to 
prescribe SP/IPTp was a result of this contraindication. HIV prevalence among pregnant women 
in Kenya was 8% in 2008-2009.
6
 Previous studies on this topic have found the availability of 
water and cups to be positive predictors of SP/IPTp uptake, but this study was only able to 
account for the “most common” water source used by the facility, which may neglect some 
21 
 
important information about its true availability and cup stock information is unavailable. 
Unfortunately, this study is unable to account for either actual or perceived level of malaria 
transmission, which varies dramatically across Kenya. Upon grouping regions according to their 
overall malaria prevalence status, a statistically significant effect was not found. The ability to 
utilize smaller geographic areas and their relevant transmission level may reveal more of an 
association. Additionally, although IPTp training, and its timing, was documented in the dataset, 
it is impossible to determine the quality of the training nor the provider’s understanding of the 
material covered. Furthermore, the enabling environment is incredibly complex, making it hard to 
truly capture what may be driving SP/IPTp prescription. 
 
Despite these weaknesses, the Kenya Service Provision Assessment collected a large, 
representative sample of facilities, ANC clients, and ANC providers, which allows for these 
results to likely be generalizable at the country level. The survey provided comprehensive facility 
data but also sufficient information on clients and providers to control for a variety of potential 
confounders. Additionally, the outcome variable measured the prescription of SP/IPTp, allowing 
us to focus on the behavior of the provider rather than the client. To the author’s knowledge, this 
is the first study to quantitatively study the intersection of facility, service, and client 
characteristics to predict SP/IPTp prescription.  
 
Conclusion  
 
 
Malaria in pregnancy poses great risks to both the mother and the fetus, especially in Kenya 
where nearly 70% of the population is at risk of malaria.
5
 Despite high ANC attendance in 2010, 
only 46% of women received at least one dose, and 25% received >2 doses of SP during their last 
pregnancy in the previous two years.
9
 The results of this study may help to inform the MOPHS 
and their partner organizations about barriers to effective SP/IPTp coverage at the facility level 
22 
 
and ways to address these missed opportunities. The study confirmed that facility managing 
authority, SP availability, and number of previous SP doses all significantly impact provider 
SP/IPTp prescription. It will be important to continue to explore the impacts of facility-level and 
service-provider characteristics on SP/IPTp prescription to ensure that women attending ANC are 
receiving effective malaria prevention resulting in healthier mothers and babies.  
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